BioDiscovery sells its subsidiary **Corvidia** to **Novo Nordisk**. The company had previously secured a $60 million Series B round in 2018, led by BioDiscovery’s fifth fund alongside Venrock, Cormorant, HBM, and investors including Sofinnova, Apple Tree, AstraZeneca, and Fresenius. Corvidia specializes in AI-driven drug discovery and development.

Jun 2020ANDERA PARTNERSNews article

Andera Partners (formerly Edmond de Rothschild Investment Partners) raises a €345 million BioDiscovery 5 fund, targeting life sciences investments in Europe. The fund follows a series of dedicated life sciences funds dating back to 2001, positioning Andera as a leader in the sector. The oversubscribed capital underscores strong demand for early-stage biotech and healthcare innovation.

May 2018ICRNews article

Crescendo Biologics Ltd. secures $70 million (€57 million) in Series B funding. The round is led by Andera Partners alongside Europe’s largest life science fund, Biodiscovery V. The company focuses on advancing biologics development for therapeutic applications.

May 2018ANDERA PARTNERSNews article

Crescendo Biologics secures a €345 million Series B funding round to advance its antibody-based cancer therapies. The round is led by Andera Partners (formerly Edmond de Rothschild) through its Biodiscovery V fund, with participation from Sofinnova Partners, EMBL, and Takeda Ventures. The capital supports further development of the company’s therapeutic pipeline targeting oncology.

Apr 2018Labiotech.euNews article